Metabolic engineering of Arabidopsis for butanetriol production using bacterial genes

Includes bibliographical references (pages 119-120).1,2,4-butanetriol (butanetriol) is a useful precursor for the synthesis of the energetic material butanetriol trinitrate and several pharmaceutical compounds. Bacterial synthesis of butanetriol from xylose or arabinose takes place in a pathway that requires four enzymes. To produce butanetriol in plants by expressing bacterial enzymes, we cloned native bacterial or codon optimized synthetic genes under different promoters into a binary vector and stably transformed Arabidopsis plants. Transgenic lines expressing introduced genes were analyzed for the production of butanetriol using gas chromatography coupled to mass spectrometry (GC-MS). Soil-grown transgenic plants expressing these genes produced up to 20 µg/g of butanetriol. To test if an exogenous supply of pentose sugar precursors would enhance the butanetriol level, transgenic plants were grown in a medium supplemented with either xylose or arabinose and the amount of butanetriol was quantified. Plants expressing synthetic genes in the arabinose pathway showed up to a forty-fold increase in butanetriol levels after arabinose was added to the medium. Transgenic plants expressing either bacterial or synthetic xylose pathways, or the arabinose pathway showed toxicity symptoms when xylose or arabinose was added to the medium, suggesting that a by-product in the pathway or butanetriol affected plant growth. Furthermore, the metabolite profile of plants expressing arabinose and xylose pathways was altered. Our results demonstrate that bacterial pathways that produce butanetriol can be engineered into plants to produce this chemical. This proof-of-concept study for phytoproduction of butanetriol paves the way to further manipulate metabolic pathways in plants to enhance the level of butanetriol production.Published with support from the Colorado State University Libraries Open Access Research and Scholarship Fund

Oral diclofenac potassium versus hyoscine-N-butyl bromide for pain relief during copper intrauterine device insertion: randomized clinical trial

Background: Present study was carried out to compare the analgesic effect of oral diclofenac potassium versus hyoscine-N-butyl bromide (HBB) for pain relief during copper intrauterine device (IUD) insertion.Methods: It was a a randomized clinical trial carried out at Assiut University Hospital, Assiut, Egypt. Parous women eligible for Copper IUD insertion were recruited and randomized in a 1:1 ratio to diclofenac potassium or HBB. The participants were asked to take 2 tablets of the study medications 30 minutes before IUD insertion. The primary outcome was the participant's self-rated pain perception using a 10-cm Visual Analogue Scale (VAS) during IUD insertion. We considered a 1.5 cm difference in VAS scores between study groups as clinically significant.Results: One hundred eight women were enrolled (n=54 in each group). Diclofenac significantly has lower mean pain score during speculum placement (1.73 vs. 2.13) and tenaculum placement (1.85 vs. 2.3) than HBB with p<0.001. No statistical significant differences between both groups in other steps of IUD insertion. Additionally, the duration of IUD insertion was significantly lower in the diclofenac group (5.34±0.76 vs. 5.74±1.23 minutes, p=0.045). No women reported side effects in both groups.Conclusions: The use of oral diclofenac potassium 30 minutes prior to copper IUD insertion slightly reduce the insertional pain and duration than oral HBB with no adverse effects

Therapeutic effect of antimyeloma antibodies conjugated with gold nanoparticles on the growth of myeloma cell line

Nanobiotechnology is a field of biomedical application of nanosize system which is a rapidly developing area within nanotechnology among these nonmaterial, gold nanoparticles (AuNPs) which receive a significant attention due to their unique physical, chemical and biological properties. AuNPs and bio-conjugated AuNPs have been widely used in cancer treatment besides other application on cancer detection and diagnosis. In this study the potential therapeutic effects of polyclonal Antimyeloma antibody (AbMM) conjugated to AuNPs in comparison with naked (AbMM) or AuNPs alone in modulation of proliferation capacity in vitro and different stages of MM cell cycle have been evaluated besides evaluation of their effects on tumor growth delay. Effect of AuNPs , (AbMM) and (Nanogold -Antimyeloma Antibodies conjugate) (gold-AbMM) on growth of myeloma cells showed decreasing in multiple myeloma SP2OR (MM) viability with increasing dose of these treatments compared to that of control also a significant enhancement in the apoptosis after conjugation of Nanogold to the Antimyeloma was observed. The induction of apoptosis with gold-AbMM was significantly higher than the MM cells exposed to only AbMM or AuNPs. The study concluded that the efficacy of (gold-AbMM) on induced myeloma growth inhibition is better than that of individual AuNPs and AbMM

GLOBAL METHYLATION PATTERN CHANGES IN BREAST AND COLORECTAL CANCER CELLS TREATED WITH DIFFERENT CHEMOTHERAPEUTIC DRUGS

Cancer in a global threat as it is considered the primary cause of death worldwide. Breast cancer is the most common cancer I female worldwide. In the present study we evaluated the role of temozolomide, carboplatin, sodium phenylbutyrate, and cyclophosphamide in changing the methylation landscape of four tumor cell liness; breast, colorectal, lung, and cervical. Cells were treated with 5 µM of each drug and the cells were incubated with the drugs for 48 and 96 h before reading the changes in methylation patterns. Global methylation quantification was measured in cells after being treated with the drugs. Data obtained indicated that sodium phenylbutyrate, followed by temozolomide were the drugs most efficient in hypermethylation of the DNA, while carboplatin followed by cyclophosphamide were able to reduce the concentration of 5-mC in the DNA. It has been concluded that using carboplatin in combination with sodium phenylbutyrate (PBA) might induce cell cycle arrest of malignant cells. Further studies are needed to highlight the mechanism of action of these drugs when combined in treatment of cancer. Keywords: methylation; breast; colon; lung; cervical; epigenetics

Amorphous Mo₅O₁₄-Type/Carbon Nanocomposite with Enhanced Electrochemical Capability for Lithium-Ion Batteries

An amorphous MomO3m−1/carbon nanocomposite (m ≈ 5) is fabricated from a citrate–gel precursor heated at moderate temperature (500 °C) in inert (argon) atmosphere. The as-prepared Mo5O14-type/C material is compared to α-MoO3 synthesized from the same precursor in air. The morphology and microstructure of the as-prepared samples are characterized by scanning electron microscopy (SEM), X-ray diffraction (XRD), and Raman scattering (RS) spectroscopy. Thermal gravimetry and elemental analysis indicate the presence of 25.8 ± 0.2% of carbon in the composite. The SEM images show that Mo5O14 is immersed inside a honeycomb-like carbon matrix providing high surface area. The RS spectrum of Mo5O14/C demonstrates an oxygen deficiency in the molybdenum oxide and the presence of a partially graphitized carbon. Outstanding improvement in electrochemical performance is obtained for the Mo5O14 encapsulated by carbon in comparison with the carbon-free MoO3. View Full-Tex

Structural and Electrochemical Properties of the High Ni Content Spinel LiNiMnO4

This work presents a contribution to the study of a new Ni-rich spinel cathode material, LiNiMnO4, for Li-ion batteries operating in the 5-V region. The LiNiMnO4 compound was synthesized by a sol-gel method assisted by ethylene diamine tetra-acetic acid (EDTA) as a chelator. Structural analyses carried out by Rietveld refinements and Raman spectroscopy, selected area electron diffraction (SAED) and X-ray photoelectron (XPS) spectroscopy reveal that the product is a composite (LNM@NMO), including non-stoichiometric LiNiMnO4-δ spinel and a secondary Ni6MnO8 cubic phase. Cyclic voltammetry and galvanostatic charge-discharge profiles show similar features to those of LiNi0.5Mn1.5O4 bare. A comparison of the electrochemical performances of 4-V spinel LiMn2O4 and 5-V spinel LiNi0.5Mn1.5O4 with those of LNM@NMO composite demonstrates the long-term cycling stability of this new Ni-rich spinel cathode. Due to the presence of the secondary phase, the LNM@NMO electrode exhibits an initial specific capacity as low as 57 mAh g−1 but shows an excellent electrochemical stability at 1C rate for 1000 cycles with a capacity decay of 2.7 × 10−3 mAh g−1 per cycle

Parkinson’s-adapted cognitive stimulation therapy: a pilot randomized controlled clinical trial

© The Author(s), 2019. Cognitive stimulation therapy (CST) is widely used with people with dementia, but there is no evidence of its efficacy in mild cognitive impairment or dementia in Parkinson’s disease (PD-MCI; PDD) or dementia with Lewy bodies (DLB). We aimed to explore the impact of ‘CST-PD’, which is home-based, individualized CST adapted for this population. In a single-blind, randomized controlled exploratory pilot trial (RCT), we randomized 76 participant–dyads [PD-MCI (n = 15), PDD (n = 40), DLB (n = 21) and their care partners] to CST-PD or treatment as usual (TAU). CST-PD involves home-based cognitively stimulating and engaging activities delivered by a trained care partner. Exploratory outcomes at 12 weeks included cognition (Addenbrooke’s Cognitive Evaluation; ACE-III), neuropsychiatric symptoms and function. In care partners, we assessed burden, stress and general health status. Relationship quality and quality of life were assessed in both dyad members. At 12 weeks, the ACE-III showed a nonstatistically significant improvement in the CST-PD group compared with the TAU group, although neuropsychiatric symptoms increased significantly in the former. In contrast, care partners’ quality of life (d = 0.16) and relationship quality (‘satisfaction’, d = 0.01; ‘positive interaction’, d = 0.55) improved significantly in the CST-PD group, and care burden (d = 0.16) and stress (d = 0.05) were significantly lower. Qualitative findings in the CST-PD recipients revealed positive ‘in the moment’ responses to the intervention, supporting the quantitative results. In conclusion, care-partner-delivered CST-PD may improve a range of care-partner outcomes that are important in supporting home-based care. A full-scale follow-up RCT to evaluate clinical and cost effectiveness is warranted

Arabidopsis thaliana PGR7 Encodes a Conserved Chloroplast Protein That Is Necessary for Efficient Photosynthetic Electron Transport

A significant fraction of a plant's nuclear genome encodes chloroplast-targeted proteins, many of which are devoted to the assembly and function of the photosynthetic apparatus. Using digital video imaging of chlorophyll fluorescence, we isolated proton gradient regulation 7 (pgr7) as an Arabidopsis thaliana mutant with low nonphotochemical quenching of chlorophyll fluorescence (NPQ). In pgr7, the xanthophyll cycle and the PSBS gene product, previously identified NPQ factors, were still functional, but the efficiency of photosynthetic electron transport was lower than in the wild type. The pgr7 mutant was also smaller in size and had lower chlorophyll content than the wild type in optimal growth conditions. Positional cloning located the pgr7 mutation in the At3g21200 (PGR7) gene, which was predicted to encode a chloroplast protein of unknown function. Chloroplast targeting of PGR7 was confirmed by transient expression of a GFP fusion protein and by stable expression and subcellular localization of an epitope-tagged version of PGR7. Bioinformatic analyses revealed that the PGR7 protein has two domains that are conserved in plants, algae, and bacteria, and the N-terminal domain is predicted to bind a cofactor such as FMN. Thus, we identified PGR7 as a novel, conserved nuclear gene that is necessary for efficient photosynthetic electron transport in chloroplasts of Arabidopsis